Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen.

Verschraegen CF, Arias-Pulido H, Lee S-J, et al. "Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen." Ann. Oncol.. 2012;23(3):785-90.